Our Take
Biogen is making a rational but high-risk bet: bet the farm on a single drug franchise rather than invest in Apellis' early-stage pipeline.
Why it matters
The $5.6bn acquisition was supposed to diversify Biogen's aging neurology portfolio. Cutting 70% of what you bought is either sound portfolio surgery or a signal that the deal was overpriced and poorly understood before close.
Do this week
Biotech investors: pressure your portfolio companies to publish post-close integration plans within 60 days of announcement, not three months after.
Biogen dismantles most of Apellis' research portfolio
Biogen announced this week that it is pausing or terminating investment in most of Apellis Pharmaceuticals' legacy research programmes following its $5.6bn acquisition three months prior. The company is also cutting a small number of research staff from Apellis' R&D team.
Two Phase II clinical trials have already moved to 'suspended' status on ClinicalTrials.gov. A trial of Empaveli (pegcetacoplan) in delayed graft function (DGF) lists "ongoing strategic evaluation of the programme" as the reason. A second trial in focal segmental glomerulosclerosis (FSGS), another rare kidney disease, cites the same reason plus "recruitment challenges including screening failures."
The status of Apellis' preclinical pipeline is unclear. This includes an undisclosed RNA-based therapy, an oral complement inhibitor, and two gene-edited therapies. Biogen has not disclosed which programmes will be retained or terminated.
The company is preserving one asset: a Phase II study combining Syfovre (pegcetacoplan) with APL-3007, an RNA interference complement C3 inhibitor, in geographic atrophy. That trial remains listed as recruiting on ClinicalTrials.gov.
One drug, two commercial indications
The pattern is clear: Biogen is consolidating around pegcetacoplan, which it markets as Empaveli for three rare disease indications and as Syfovre for geographic atrophy. GlobalData (analyst estimate) projects the pegcetacoplan franchise will generate $785m in revenue by 2032.
When Biogen announced the deal in March, the stock fell 4% on concerns about the acquisition price. William Blair analysts defended the purchase at the time, projecting it would add $1.54bn in sales by 2030 and offset declining revenue from Biogen's multiple sclerosis franchise.
The rapid pipeline cull raises a question: did Biogen overpay for a company whose early-stage science it did not intend to pursue? Or did the company correctly identify that Apellis' commercial value lay entirely in its approved therapies, making the research programmes optional? The timing suggests the former. Most acquirers conduct detailed due diligence before close. Deciding to cut 70% of your target's pipeline three months post-signing indicates either poor pre-deal analysis or post-deal pivoting.
What acquirers actually prioritize
Biogen's move is not unusual in pharma. Cash-strapped biotech companies are often acquired for a single asset, and large pharma typically deprioritizes early-stage work in favour of rapid revenue generation. The risk is real: if Empaveli or Syfovre face safety signals, efficacy questions, or commercial headwinds, Biogen has no pipeline insurance and a $5.6bn hole on the balance sheet.
Biogen is doubling down on this strategy. The company recently acquired immunology specialist RayThera for $1bn, signalling a pattern of buying revenue rather than building it.